Login
$MREO
$0.30 -$0.00 (0.85%) After hours

$MREO SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI)

28 Oct 2026 SCHEDULE 13G/A
19 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a written notice (the “First Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in...

14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

11 Aug 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

15 May 2026 SCHEDULE 13G/A
14 May 2026 SCHEDULE 13G
14 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 14, 2026, Mereo BioPharma Group plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 436,766,255 ord...

12 May 2026 8-K/A: Results of Operations and Financial Condition

London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026...

12 May 2026 10-Q
12 May 2026 8-K: Completion of Acquisition or Disposition of Assets

London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026...

09 Apr 2026 ARS
09 Apr 2026 Proxy statement: annual meeting on May 14, 2026
27 Mar 2026 PRE 14A
27 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc. (the “Company”) that she will not stand for re-election as a Director of the Board of Directors (the “Board”) of the Company at the Company’s 2026 annual general meeti...

19 Mar 2026 10-K
19 Mar 2026 8-K: Results of Operations and Financial Condition

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support